{
    "name": "nitroglycerin IV",
    "comment": "Rx",
    "other_names": [
        "glyceryl trinitrate IV",
        "IV Nitroglycerin",
        "NitroBid IV",
        "NTG",
        "Tridil"
    ],
    "classes": [
        "Nitrates",
        "Angina"
    ],
    "source": "https://reference.medscape.com/drug/glyceryl-trinitrate-iv-iv-nitroglycerin-nitroglycerin-iv-342278",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitroglycerin and any potential adverse effects on breastfed child from nitroglycerin or from underlying maternal condition"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for nitroglycerin and any potential adverse effects on breastfed child from nitroglycerin or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Recent use (within several days) of PDE-5 inhibitors (eg, avanafil, sildenafil, tadalafil, or vardenafil) may cause dangerously low hypotension; the time course of the interaction appears to be related to the PDE-5 inhibitor half-life",
                "Riociguat; coadministration may cause hypotension",
                "Narrow angle glaucoma (controversial: may not be clinically significant)",
                "Hypersensitivity",
                "Symptomatic hypotension, uncorrected hypovolemia, increased intracranial pressure (head trauma, cerebral hemorrhage), severe anemia, constrictive pericarditis, pericardial tamponade, restrictive cardiomyopathy"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use caution in alcohol use, hyperthyroidism, hypertrophic cardiomyopathy, postural hypotension, severe renal impairment, hepatic impairment",
                "Gradually decrease dose to avoid withdrawal reaction",
                "May need 10-12 hr/day nitrate-free interval to avoid tolerance development",
                "Doses ~ 200 mcg/min",
                "Some products contain alcohol and propylene glycol",
                "Remove topical forms when starting IV infusion",
                "Use glass bottles and non-PVC (polyvinyl chloride) tubing to avoid adsorption of drug to delivery devices; use of PVC tubing in infusion sets may lead to loss of active ingredient due to adsorption of nitroglycerin to PVC tubing; dosage is affected; adsorption by PVC tubing is increased when tubing is long, flow rates are low, and nitroglycerin concentration of solution is high; delivered fraction of solution's original nitroglycerin content has been 20-60% in published studies; fraction varies with time during single infusion, and no simple correction factor can be used; if intravenous nitroglycerin is administered through non-adsorptive tubing, doses based upon published reports will generally be too high; some in-line intravenous filters also adsorb nitroglycerin and should be avoided",
                "Solutions containing dextrose without electrolytes should not be administered through the same administration set as blood, as this may result in pseudoagglutination or hemolysis",
                "Intravenous administration of solutions may cause fluid overloading resulting in dilution of serum electrolyte concentrations, overhydration and congested states of pulmonary edema; risk of dilutional states is inversely proportional to electrolyte concentrations of injections; risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to electrolyte concentration of injections",
                "Severe hypotension and shock may occur with even small doses of nitroglycerin; monitor patients who may be volume depleted or, for whatever reason, are already hypotensive; hypotension induced by nitroglycerin may be accompanied by paradoxical bradycardia and increased angina pectoris",
                "Nitrate therapy may aggravate angina caused by hypertrophic cardiomyopathy",
                "Tolerance development and occurrence of cross tolerance to other nitro compounds reported",
                "Administer nitroglycerin in 5% dextrose Injection only via infusion pump that can maintain constant infusion rate",
                "Monitor patients with known sub-clinical or overt diabetes mellitus when using solutions containing dextrose",
                "Cases of methemoglobinemia reported with moderate doses of organic nitrates; when methemoglobinemia is diagnosed, discontinue treatment of nitroglycerin; if condition not reversed, treat with methylene blue, 1-2 mg/kg intravenously",
                "Protect from freezing and light",
                "Do not change brands unintentionally as not all are bioequivalent",
                "Treat drug-induced headache with aspirin or acetaminophen",
                "Provide nitrate-free interval (10-12 hr or overnight) to avoid development of tolerance",
                "Use supportive treatment in overdose; there is no specific antidote for overdose; risk of overdose can be minimized by close monitoring during treatment"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "The vasodilating effects of nitroglycerin may be additive with those of other antihypertensives. (e.g., beta-blockers, calcium channel blockers and tricyclic antidepressants) and may cause increased hypotensive effects",
                        "Concomitant use of nitroglycerin in 5% dextrose injection concomitant use with phosphodiesterase inhibitors (e.g. sildenafil, tadalafil, or vardenafil) in any form is contraindicated",
                        "Concomitant use of nitroglycerin in 5% dextrose injection with riociguat, a soluble guanylate cyclase stimulator, can cause hypotension and is contraindicated",
                        "Marked symptomatic orthostatic hypotension reported when calcium channel blockers and organic nitrates used in combination",
                        "Nitroglycerin at higher dosages may interfere with anticoagulant effect of heparin; intravenous nitroglycerin can induce heparin resistance"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "avanafil",
            "description": {
                "common": "nitroglycerin IV, avanafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "bromocriptine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cabergoline",
            "description": {
                "common": "cabergoline decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dihydroergotamine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "dihydroergotamine intranasal decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "ergoloid mesylates decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergotamine",
            "description": {
                "common": "ergotamine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "methylergonovine decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "riociguat",
            "description": {
                "common": "nitroglycerin IV, riociguat.\nEither increases effects of the other by additive vasodilation. Contraindicated. Coadministration of nitrates or nitric oxide donors is contraindicated due to risk of hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sildenafil",
            "description": {
                "common": "nitroglycerin IV, sildenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tadalafil",
            "description": {
                "common": "nitroglycerin IV, tadalafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "vardenafil",
            "description": {
                "common": "nitroglycerin IV, vardenafil. Mechanism: additive vasodilation. Contraindicated. Potentially fatal hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabergoline",
            "description": {
                "common": "nitroglycerin IV increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "nitroglycerin IV increases effects of ergoloid mesylates by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergotamine",
            "description": {
                "common": "nitroglycerin IV increases effects of ergotamine by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofexidine",
            "description": {
                "common": "lofexidine, nitroglycerin IV.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "nitroglycerin IV increases effects of methylergonovine by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arginine",
            "description": {
                "common": "nitroglycerin IV, arginine. Mechanism: additive vasodilation. Use Caution/Monitor. Possible hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benazepril",
            "description": {
                "common": "nitroglycerin IV, benazepril.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "nitroglycerin IV, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "nitroglycerin IV, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "nitroglycerin IV increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracaine",
            "description": {
                "common": "tetracaine, nitroglycerin IV. Other (see comment). Use Caution/Monitor. \nComment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetylcysteine",
            "description": {
                "common": "acetylcysteine increases effects of nitroglycerin IV by Other (see comment). Minor/Significance Unknown. \nComment: Acetylcysteine may enhance vasodilatory effects of nitroglycerin."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetylcysteine (Antidote)",
            "description": {
                "common": "acetylcysteine (Antidote) increases effects of nitroglycerin IV by Other (see comment). Minor/Significance Unknown. \nComment: Acetylcysteine may enhance vasodilatory effects of nitroglycerin."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "nitroglycerin IV, ethanol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "heparin",
            "description": {
                "common": "nitroglycerin IV decreases effects of heparin by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metronidazole",
            "description": {
                "common": "nitroglycerin IV, metronidazole. Mechanism: decreasing metabolism. Minor/Significance Unknown. Disulfiram like reaction."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Lightheadedness",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Flushing",
            "percent": null
        },
        {
            "name": "N",
            "percent": null
        },
        {
            "name": "V",
            "percent": null
        },
        {
            "name": "Nervousness",
            "percent": null
        },
        {
            "name": "Xerostomia",
            "percent": null
        },
        {
            "name": "Methemoglobinemia",
            "percent": null
        },
        {
            "name": "rare",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Prolonged bleeding time",
            "percent": null
        },
        {
            "name": "Exfoliative dermatitis",
            "percent": null
        },
        {
            "name": "Unstable angina",
            "percent": null
        },
        {
            "name": "Rebound hypertension",
            "percent": null
        },
        {
            "name": "Thrombocytopenia",
            "percent": null
        }
    ]
}